ERBB2 and neoplasm: In parallel to anti-HER2 targeted nanomedicines, nanotherapies that specifically attack other molecules important for HER2 tumor behavior have obtained promising preclinical results, even as a novel way to limit resistance to anti-HER2 drugs [45].